Hyderabad-based Finoso Pharma Private Limited, a formulation development company, on Thursday formed a 50:50 joint venture (JV) with US-based CritiTech Inc, a drug development company.
The joint venture will provide alternative API (active pharmaceutical ingredient) size reduction technology and particle design services to the pharmaceutical industry with associated formulation services to meet the research and development (R&D) and the early-clinical trial supply needs.
The focus will be on generic components and on therapeutic areas including anti-cancer and lung disease areas.
No comments:
Post a Comment